Farhad Ravandi

68.3k total citations · 7 hit papers
1.3k papers, 34.7k citations indexed

About

Farhad Ravandi is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Farhad Ravandi has authored 1.3k papers receiving a total of 34.7k indexed citations (citations by other indexed papers that have themselves been cited), including 1.1k papers in Hematology, 591 papers in Genetics and 409 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Farhad Ravandi's work include Acute Myeloid Leukemia Research (768 papers), Chronic Myeloid Leukemia Treatments (469 papers) and Acute Lymphoblastic Leukemia research (406 papers). Farhad Ravandi is often cited by papers focused on Acute Myeloid Leukemia Research (768 papers), Chronic Myeloid Leukemia Treatments (469 papers) and Acute Lymphoblastic Leukemia research (406 papers). Farhad Ravandi collaborates with scholars based in United States, Germany and France. Farhad Ravandi's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Elias Jabbour, Gautam Borthakur, Susan O’Brien, Tapan M. Kadia, Stefan Faderl, Marina Konopleva and Naval Daver and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Farhad Ravandi

1.2k papers receiving 34.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Decitabine improves patient outcomes in myelodysplastic syndromes

2006 1.1k citations Hagop M. Kantarjian, Jean‐Pierre J. Issa et al. Cancer profile →
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

2006 515 citations Hagop M. Kantarjian, Guillermo Garcia‐Manero et al. Blood profile →
Acute myeloid leukemia: current progress and future directions

2021 471 citations Hagop M. Kantarjian, Tapan M. Kadia et al. profile →
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

2020 243 citations Nicholas J. Short, Marina Konopleva et al. profile →
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

2020 207 citations Nicholas J. Short, Roland B. Walter et al. profile →
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

2021 148 citations Koji Sasaki, Farhad Ravandi et al. Cancer profile →

Peers

Countries citing papers authored by Farhad Ravandi

Since Specialization

Citations

This map shows the geographic impact of Farhad Ravandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farhad Ravandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farhad Ravandi more than expected).

Fields of papers citing papers by Farhad Ravandi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farhad Ravandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farhad Ravandi. The network helps show where Farhad Ravandi may publish in the future.

Co-authorship network of co-authors of Farhad Ravandi

This figure shows the co-authorship network connecting the top 25 collaborators of Farhad Ravandi. A scholar is included among the top collaborators of Farhad Ravandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farhad Ravandi. Farhad Ravandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis 2025 ·Blood ·(unknown), Hagop Kantarjian, Koji Sasaki, Nitin B. Jain, Caitlin R. Rausch, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero, Danielle Hammond, Mahesh Swaminathan, (unknown), Maro Ohanian, Rebecca Garris, Nicholas J. Short, Elias Jabbour	0
2	Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up 2024 ·Blood ·Jayastu Senapati, H. Kantarjian, Edward Ayoub, (unknown), Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yılmaz, Keyur P. Patel, (unknown), Sherry Pierce, Guillermo Garcia‐Manero, Farhad Ravandi, Gautam Borthakur	1
3	Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) 2024 ·Blood ·(unknown), Álex Bataller, Alexandre Bazinet, Gautam Borthakur, Elias Jabbour, (unknown), Nicholas J. Short, Koichi Takahashi, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban‐Bravo, William G. Wierda, Farhad Ravandi, H. Kantarjian, Tapan M. Kadia	0
4	Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center Experience 2024 ·Cancers ·David McCall, (unknown), (unknown), (unknown), (unknown), Ramya Ramakrishnan, César Núnêz, Michael Roth, (unknown), (unknown), Naval Daver, Sofía Garcés, Nicholas J. Short, Ghayas C. Issa, Farhad Ravandi, Courtney D. DiNardo, Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero, Branko Cuglievan, Tapan M. Kadia	1
5	Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia 2024 ·Blood ·Álex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, Jayastu Senapati, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban‐Bravo, Guillermo Garcia‐Manero, Farhad Ravandi, Tapan M. Kadia	3
6	Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia 2024 ·Leukemia & lymphoma ·(unknown), (unknown), Hagop M. Kantarjian, David McCue, Fadi Haddad, William G. Wierda, Alessandra Ferrajoli, Jan A. Burger, (unknown), Jeffrey L. Jorgensen, Sa A. Wang, Keyur Patel, Sanam Loghavi, Susan O’Brien, Farhad Ravandi	4
7	Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation 2024 ·American Journal of Hematology ·Jayastu Senapati, Hagop M. Kantarjian, Fadi Haddad, Nicholas J. Short, Gautam Borthakur, Rashmi Kanagal‐Shamanna, Guilin Tang, Elias Jabbour, Courtney D. DiNardo, Naval Daver, Guillermo Montalban‐Bravo, (unknown), Amin Alousi, (unknown), Uday Popat, Guillermo Garcia‐Manero, Farhad Ravandi, Tapan M. Kadia	3
8	Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia 2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Oren Pasvolsky, Rima M. Saliba, (unknown), (unknown), (unknown), Sairah Ahmed, Musa Yılmaz, Naval Daver, Farhad Ravandi, Courtney D. DiNardo, Nicholas J. Short, Tapan M. Kadia, Gheath Alatrash, May Daher, (unknown), Uday Popat, Richard Champlin, Elizabeth J. Shpall, Betül Oran	2
9	Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results 2023 ·Blood ·(unknown), Gautam Borthakur, Koji Sasaki, Guilin Tang, Guillermo Montalban‐Bravo, Elias Jabbour, Maro Ohanian, Musa Yılmaz, Fadi Haddad, Kelly S. Chien, Jo Ishizawa, Nicholas J. Short, Abhishek Maiti, Mahesh Swaminathan, Guillermo Garcia‐Manero, Naval Daver, Courtney D. DiNardo, Farhad Ravandi, Tapan M. Kadia	0
10	Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia 2021 ·Blood ·Danielle Hammond, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Nicholas J. Short, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Elias Jabbour, Kelly S. Chien, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo	1
11	Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 2021 ·American Journal of Hematology ·Koji Sasaki, Elias Jabbour, Nicholas J. Short, Nitin Jain, Farhad Ravandi, Ching‐Hon Pui, Hagop M. Kantarjian	79
12	Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs 2019 ·Blood Advances ·Preetesh Jain, Hagop M. Kantarjian, Prajwal Boddu, Graciela M. Nogueras‐González, Srđan Verstovšek, Guillermo Garcia‐Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, (unknown), (unknown), Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jörge E. Cortes	85
13	Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience 2018 ·Blood ·Mansour Alfayez, Hagop M. Kantarjian, Tapan M. Kadia, Guillermo Garcia‐Manero, Farhad Ravandi, Gautam Borthakur, Courtney D. DiNardo, Mary Beth Rios, Elias Jabbour, Jörge E. Cortes	1
14	Monoclonal antibodies in acute lymphoblastic leukemia 2015 ·Blood ·Elias Jabbour, Susan O’Brien, Farhad Ravandi, Hagop M. Kantarjian	111
15	Reversal of Acquired Drug Resistance in FLT3 -Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies 2014 ·Clinical Cancer Research ·Weiguo Zhang, Gao Chen, Marina Konopleva, Ye Chen, Rodrigo Jácamo, Gautam Borthakur, Jörge E. Cortes, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff	42
16	Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia breakdown → 2012 ·Journal of Clinical Oncology ·Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska, Agnieszka Wierzbowska, Grzegorz Mazur, Jiří Mayer, Jyh-Pyng Gau, Wen‐Chien Chou, Rena Buckstein, Jaroslav Čermák, Ching-Yuan Kuo, Albert Oriol, Farhad Ravandi, Stefan Faderl, Jacques Delaunay, Daniel Lysák, Mark D. Minden, Christopher Arthur	818
17	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors 2011 ·Blood ·Mariela Sivina, Robert J. Kreitman, Amnon Peled, Farhad Ravandi, Jan A. Burger	10
18	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment 2011 ·Journal of Clinical Oncology ·Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jörge E. Cortes, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey	244
19	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome 2008 ·Blood ·Stefan Faderl, Farhad Ravandi, Xuelin Huang, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Zeev Estrov, Gautam Borthakur, Srđan Verstovšek, Deborah A. Thomas, Monica Kwari, Hagop M. Kantarjian	151
20	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome 2007 ·Cancer ·Hagop M. Kantarjian, Susan O’Brien, Xuelin Huang, Guillermo Garcia‐Manero, Farhad Ravandi, Jörge E. Cortes, Jianqin Shan, Jan Davisson, Carlos E. Bueso‐Ramos, Jean‐Pierre J. Issa	132

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact